Patients can benefit both financially and clinically by enrolling in ongoing clinical trials, said Eric Lander, MD.

Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney ...

For patients with obesity, clinicians should move beyond a "try and fail" approach to lifestyle interventions and prioritize ...

Widespread noncompliance with federal cost-sharing rules exists, particularly impacting Medicare beneficiaries and ...

It's a critical time to spotlight the dire health disparities affecting Black Americans, from premature deaths to maternal ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

FDA approves Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in ...

In this interview with TRUST-I and TRUST-II trial investigator, Jorge J. Nieva, MD, USC Keck School of Medicine, he walks through the design of the trials, the results that supported the FDA approval, ...

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...

Panelists discuss how minimal residual disease (MRD) status can guide post-transplant treatment decisions, particularly for high-risk patients who don’t achieve MRD negativity and patients considering ...

Panelists discuss how implementing cardiovascular-kidney-metabolic health requires a team-based approach using the analogy of football, where physicians coach multidisciplinary teams to help patients ...